Cardlytics, Inc. (NASDAQ:CDLX) Stock Position Reduced by Acorn Financial Advisory Services Inc. ADV

Acorn Financial Advisory Services Inc. ADV lessened its position in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 13.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 122,928 shares of the company’s stock after selling 18,462 shares during the period. Acorn Financial Advisory Services Inc. ADV’s holdings in Cardlytics were worth $1,132,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Rhumbline Advisers lifted its holdings in Cardlytics by 2.6% during the 1st quarter. Rhumbline Advisers now owns 34,150 shares of the company’s stock worth $1,878,000 after buying an additional 856 shares during the last quarter. FMR LLC raised its position in shares of Cardlytics by 238.4% during the 2nd quarter. FMR LLC now owns 1,428 shares of the company’s stock worth $32,000 after purchasing an additional 1,006 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Cardlytics by 7.2% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,580 shares of the company’s stock worth $392,000 after purchasing an additional 1,184 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Cardlytics by 186.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,137 shares of the company’s stock worth $35,000 after purchasing an additional 1,391 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in shares of Cardlytics by 10.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,738 shares of the company’s stock worth $93,000 after purchasing an additional 1,436 shares during the period. Institutional investors own 68.10% of the company’s stock.

Cardlytics Stock Performance

CDLX opened at $13.60 on Wednesday. Cardlytics, Inc. has a 1 year low of $2.59 and a 1 year high of $20.52. The company has a debt-to-equity ratio of 1.91, a current ratio of 1.31 and a quick ratio of 1.31. The stock has a fifty day moving average price of $8.39 and a 200 day moving average price of $9.94.

Insider Buying and Selling at Cardlytics

In related news, major shareholder Clifford Sosin bought 311,715 shares of the business’s stock in a transaction on Friday, March 15th. The shares were bought at an average cost of $13.71 per share, for a total transaction of $4,273,612.65. Following the completion of the acquisition, the insider now directly owns 5,673,676 shares in the company, valued at $77,786,097.96. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In other Cardlytics news, major shareholder Clifford Sosin acquired 311,715 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were acquired at an average cost of $13.71 per share, for a total transaction of $4,273,612.65. Following the completion of the purchase, the insider now owns 5,673,676 shares of the company’s stock, valued at approximately $77,786,097.96. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Karim Saad Temsamani sold 31,123 shares of Cardlytics stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $7.77, for a total value of $241,825.71. Following the sale, the chief executive officer now directly owns 277,735 shares in the company, valued at $2,158,000.95. The disclosure for this sale can be found here. Insiders have sold a total of 136,556 shares of company stock worth $926,492 over the last three months. Corporate insiders own 0.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on CDLX. Lake Street Capital raised their target price on Cardlytics from $13.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Needham & Company LLC raised their price objective on Cardlytics from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Finally, Craig Hallum raised Cardlytics from a “hold” rating to a “buy” rating and raised their price objective for the stock from $10.00 to $18.00 in a research note on Friday, March 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $13.20.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.